Last updated: February 14, 2026
Overview
NDC 64950-0211 is a biosimilar product marketed by Celltrion, Inc., identified as Herzuma (trastuzumab-pkrb). It is a biosimilar to Roche's Herceptin (trastuzumab) indicated primarily for HER2-positive breast cancer and gastric cancer. The biosimilar regulatory approval occurred in the U.S. in 2019, with commercialization focused on competitive entry into the oncology biosimilar market.
Market Size and Demand
The global HER2-positive breast cancer market was valued at approximately $3.5 billion in 2022, with a CAGR forecast of 8% through 2030 due to increasing incidence rates and improved diagnosis. The U.S. accounts for 40% of this market, translating to roughly $1.4 billion in 2022.
Key Market Drivers
- Patent expirations: Roche’s Herceptin patents expired in 2019, opening the market for biosimilar competition.
- Pricing pressure: Biosimilars typically price 15-30% below originator products, stimulating market penetration.
- Clinician acceptance: Growing confidence in biosimilars enhances adoption for approved indications.
- Policy incentives: CMS and other payers incentivize biosimilar use through formulary preferences and reimbursement policies.
Current Market Share and Competition
Herzuma's market share in the U.S. remains modest but growing, accounting for approximately 12% of trastuzumab prescriptions as of 2022, with competing biosimilars (e.g., Ogivri, Kanjinti) also vying for market share.
| Product |
Estimated U.S. Market Share (2022) |
List Price (approximate) |
| Herceptin (originator) |
70% |
~$2,900 per 440 mg dose |
| Herzuma (biosimilar) |
12% |
~$2,500 per 440 mg dose |
| Other biosimilars |
18% |
similar pricing |
Pricing Dynamics
The average wholesale price (AWP) for Herzuma is approximately 15-20% lower than Herceptin. Discounted prices for institutions and payers often lead to further reductions — we project biosimilar prices could decrease by up to 25% by 2025 as market competition intensifies.
Market Penetration and Revenue Projections
Given current adoption trends, sales of Herzuma are projected to reach:
- 2023: $150 million in the U.S.
- 2024: $250 million as market share increases
- 2025: $350-400 million, assuming continued market penetration
In global markets, particularly in Europe, biosimilar acceptance is higher, with projected revenues exceeding $350 million in Europe alone by 2024.
Pricing Projections
Based on current trends, biosimilar trastuzumab products are expected to:
- Reduce price per dose by approximately 15% in 2023
- Achieve price reductions of 25% by 2025 as more competitors enter the market
- Maintain gross margins of approximately 35-45%, aligned with biosimilar industry standards
Regulatory and Policy Impact
Reimbursement policies will influence market acceptance. The CMS Biosimilar Policy provides a payment reduction to promote biosimilar prescriptions, which could accelerate HER2 biosimilar uptake.
Investment and R&D Outlook
Celltrion’s ongoing biosimilar pipeline targets expansions into new indications and aggressive market share growth. The strategic focus on European and Asian markets offers additional revenue channels.
Summary
- Biosimilar NDC 64950-0211, Herzuma, faces an intense competitive landscape, with expanding market share driven by pricing and clinician acceptance.
- Revenue growth is projected to reach nearly $400 million in the U.S. by 2025.
- Price reductions of up to 25% are feasible, creating a pressure on originator sales but opening opportunities in emerging markets.
Key Takeaways
- Biosimilar entry has drastically altered trastuzumab pricing and demand dynamics.
- Continued market share growth depends on regulatory policies, payer strategies, and clinician confidence.
- Price reductions remain significant, with biosimilar prices potentially falling to 75% of originator prices by 2025.
- The global market beyond the U.S. presents high growth potential, especially in Europe and Asia.
- Celltrion’s pipeline and strategic positioning aim to capitalize on the biosimilar trend.
FAQs
-
What factors influence biosimilar pricing for NDC 64950-0211?
Pricing is affected by patent status, market competition, payer negotiations, and regulatory policies.
-
How does market share of biosimilars impact revenue projections?
Increased market penetration reduces per-unit prices but can generate higher overall revenue through volume growth.
-
What is the outlook for biosimilar adoption in Europe?
European markets tend to adopt biosimilars faster due to supportive policies, with projected revenues surpassing U.S. forecasts by 2024.
-
How do reimbursement policies influence biosimilar sales?
Reimbursement incentives, formulary preferences, and price negotiations can accelerate biosimilar prescribing.
-
Are there risks that could affect revenues for Herzuma?
Regulatory delays, patent litigation, clinician skepticism, or aggressive pricing from competitors could impact sales growth.
Sources
- MarketNews (2022). HER2-positive breast cancer market valuation.
- IQVIA (2022). U.S. biosimilar landscape report.
- CMS (2022). Biosimilar reimbursement policies.
- EvaluatePharma (2023). Biosimilar pricing projections.
- Celltrion (2022). Herzuma commercial launch and pipeline updates.
